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The central role of ammonia in the pathogenesis 
of hepatic encephalopathy (HE) is well recognized 
(1). However, the measurement of ammonia for 
the management of HE is controversial. Haj and 
Rockey attempted to clarify this dispute (2) with 
a retrospective study in a large number of patients 
in a United States (US) single-centre hospital. They 
found the dose of lactulose administered to pa-
tients did not differ in those with either elevated or 
normal ammonia, concluding that ammonia levels 
do not guide therapy in the management of HE. 
This conclusion needs to be examined carefully.
In the study, 46% (551 patients) of the patients 
who were hospitalized with overt HE had ammo-
nia measured. From these measurements, 60% were 
defined as being hyperammonemic using a cut-off 
for blood ammonia of >72uM. This requires discus-
sion. First, there is a strong selection bias since 54% 
of patients diagnosed with overt HE did not have 
their ammonia measured, and no reason was pro-
vided. Second, 72 µM cut-off needs to be justified; 
this level of ammonia is exceedingly high to be de-
fined as normal since it was recently demonstrated 
that an ammonia value of 79.5 µM is independently 
associated with death within the next 28 days (3). 
Therefore, 40% patients with ‘normal’ ammonia 
levels is an overstatement and most likely inaccu-
rate, as the diagnosis of HE is not compatible with 
normal ammonia levels (4). Third, measuring am-
monia is delicate, and the acquisition of samples 
for ammonia measurement, as well as transport 
and analysis details, were not declared. Sample 
transport must be on ice to avoid erroneous values, 
and measurements must be made within 30–60 min 
(5). In addition, the reference range of ammonia, as 
well as biochemical analyzer and assay used, needs 
to be provided. The aforementioned particulars can 
impact ammonia quantitatively, which leaves the 
presented ammonia data unreliable.
The primary outcome of their retrospective 
study was the total amount of lactulose given for 
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the management of HE within the first 48 hours 
(time when 3–4 movements per day are routinely 
achieved). The authors concluded that there was 
no correlation between the amount of lactulose 
given and levels of ammonia, signifying that a 
higher blood ammonia did not entail a more ag-
gressive dose of lactulose. However, it is unclear 
what guided the dosing of lactulose. Neverthe-
less, it can be speculated that more lactulose was 
administered since either constipation was not 
resolved or HE was persisting. Furthermore, in-
dependent of whether ammonia was high or not, 
or of the precipitating event, all patients received 
similar volumes of lactulose. This is curious as, in 
clinical practice, one would primarily use lactulose 
for patients with constipation and gastrointestinal 
bleeding and considerably less in those presenting 
with diarrhea, severe dehydration, renal dysfunc-
tion, or infection (4). Remarkably, in patients for 
whom infection was the precipitating factor (42%), 
lactulose was administered. Despite this, the au-
thors focus on incomplete and potentially inaccu-
rate measurements of ammonia to conclude that 
the dose of lactulose administered was not influ-
enced by blood ammonia levels.
Finally, lactulose is a non-absorbable disaccha-
ride that acts as an osmotic laxative to treat con-
stipation, a precipitating factor of HE. In North 
America, lactulose and rifaximin are currently the 
only available options for the treatment of HE. 
Lactulose was never approved by the US Food and 
Drug Administration (FDA), and although used 
widely, there is no clear regulatory guidance on the 
indications and doses to be used. Rifaximin was 
approved by the FDA for the recurrence of HE as 
secondary prophylaxis and not for the treatment of 
an acute episode of HE-hospitalization (4). There 
is only very low-quality data on dose-response of 
ammonia reduction or HE improvement with lact-
ulose dosing. Furthermore, only a handful of trials 
exist comparing lactulose with placebo on ammo-
nia levels in the acute setting.
According to Haj and Rockey’s study, it is clear 
lactulose was not used to lower ammonia, as lactu-
lose was administered irrelevant of blood ammo-
nia levels. An efficient ammonia reducing agent 
remains an unmet care gap, which would mandate 
ammonia measurements, improve management 
(differential diagnosis), and guide appropriate 
treatment for patients suffering from HE. Further-
more, blood ammonia levels have recently been rec-
ognized as prognostic and predictive biomarkers 
for the risk of developing overt HE (3,6–8). This 
strengthens the value of monitoring and treating 
blood ammonia.
Based upon an unsound, poorly designed ret-
rospective study, we believe Haj and Rockey’s 
conclusion that ammonia levels do not change the 
management of these patients is potentially flawed. 
Prospective studies are needed to thoroughly ap-
preciate the comprehensive role ammonia plays in 
the spectrum of HE.
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